Document › Details
Lonza Group Ltd.. (8/7/13). "Press Release: Sorrento Therapeutics, Inc. Licenses Lonza’s GS Xceed Gene Expression System for the Research and Development of Human Therapeutic Antibodies". Basel & San Diego, CA.
|Organisation||Lonza Group AG|
|Today||Lonza Group (Group)|
|Group||Lonza Group (Group)|
|Organisation 2||Sorrento Therapeutics Inc. (Nasdaq: SRNE)|
|Product||GS Xceed™ Gene Expression System|
|Product 2||therapeutic antibody|
|Person||Fallen, Karen (Lonza 201308 VP Licensing + Technology Lonza Development Services)|
Sorrento Therapeutics, Inc. (OTCQB: SRNE; SRNED; Sorrento) and Lonza announced today the signing of a non-exclusive research license agreement, for access to Lonza's GS Xceed™ Gene Expression System. The GS Xceed™ System will be used in the generation of stable expression cell lines for the production and development of therapeutic antibodies in Sorrento's product portfolio.
The research license agreement will give Sorrento access to Lonza's GS technology for use in Sorrento's maturing pipeline of therapeutic antibodies in oncology, inflammation, and infectious disease. Sorrento has shown yields of up to 3g/L with the GS Xceed™ System, in the production of antibodies targeting the vascular epidermal growth factor receptor 2 (VEGFR2), an important anti-angiogenesis target for a number of solid tumor indications. Several monoclonal antibodies (mAbs) will be produced and developed under the new agreement, including Sorrento's lead anti-PD-L1 and anti-PD-1 antibodies, as well as a selection of traditionally difficult-to-obtain anti-chemokine receptor mAbs.
"We are excited to license Lonza's GS Xceed™ System for the development of our lead human therapeutic antibody programs," commented Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento Therapeutics. "The speed and ease of use of the GS Xceed™ System will aid in the rapid selection of high-producing cell lines and accelerate the production and development of our most promising therapeutic candidates."
"We look forward to supporting Sorrento's efforts to expand and develop its pipeline of promising new therapeutic candidates," said Karen Fallen, VP of Licensing and Technology, Lonza Development Services. "The GS Xceed System™ is an innovative and robust expression system derived from our industry-leading original GS System™ optimized through years of process development expertise."
About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the Unites States, Europe and additional international markets. Sorrento Therapeutics' primary therapeutic focus is oncology but it is also developing therapeutics products for other indications, including inflammation, metabolic, and infectious diseases. Sorrento Therapeutics' proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutic product candidates that bind to disease targets appropriate for antibody therapy. More information is available at www.sorrentotherapeutics.com
About the GS Xceed™ Gene Expression System™
The GS Xceed™ Gene Expression System and GS Gene Expression System™, are owned and licensed by Lonza, and used for the production of therapeutic recombinant proteins and monoclonal antibodies. Over 100 biotechnology and pharmaceutical companies and over 85 academic laboratories worldwide are successfully using the GS Gene Expression System™ which has established itself as the industry standard. The GS Xceed System™ is the second generation system to Lonza's established expression platform. Lonza's expression systems are characterized by their speed and ease of use; the higher yielding cell lines provide cost-efficient production of therapeutic proteins. Lonza's long and proven track record has made it a leader in the industry.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as "assumes," "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements about the clinical trial results from third parties, and the preclinical and clinical development of Sorrento's human antibody therapeutics. All such forward-looking statements are based on Sorrento's current beliefs and expectations, and should not be regarded as a representation by Sorrento that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Sorrento's businesses; the scope and validity of patent protection for Sorrento's platform technologies, and the risk that the development or commercialization of product candidates may infringe the intellectual property rights of others; the potential that Sorrento may require substantial additional funding in order to obtain regulatory approval for and commercialize Sorrento's proprietary G-MAB® fully-human antibody library platform technologies or product candidates; and additional risks set forth in Sorrento's filings with the Securities and Exchange Commission. These forward-looking statements represent Sorrento's judgment as of the date of this release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Sorrento undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Record changed: 2017-04-02
More documents for Lonza Group (Group)
-  Lonza Group AG. (3/16/17). "Press Release: Lonza Reveals New Portfolio of High-Quality Human and Animal Hepatocytes for ADME-Tox Testing". Cologne & Basel....
-  Lonza Group AG. (3/9/17). "Press Release: Dr. Jordan Petkov Joins Lonza Consumer Care as Global Head of Research and Technology". Allendale, NJ....
-  Sanofi S.A.. (2/27/17). "Press Release: Sanofi and Lonza Enter into a Strategic Partnership to Establish a Large-Scale Biologics Production Facility". Paris & Basel....
-  Lonza Group Ltd.. (2/16/17). "Press Release: Lonza and Selecta Biosciences Announce Manufacturing Agreement for Anc80-AAV-Based Gene Therapy for Treatment of Methylmalonic Acidemia". Basel & Watertown, MA....
-  Alcobra Ltd.. (2/15/17). "Press Release: Alcobra Announces Fourth-quarter and Full-year 2016 Financial Results and Provides Corporate Update". Tel Aviv....
-  Lonza Group AG. (2/1/17). "Press Release: Lonza Successfully Places 5.0 Million New Shares, Raising Gross Proceeds of CHF 865 Million [Not for US, CA, JP or AU]". Basel....
-  Lonza Group Ltd.. (12/15/16). "Press Release: Lonza to Acquire Capsugel to Create Leading Integrated Solutions Provider to the Global Pharma and Consumer Healthcare Industries". Basel & Morristown, NJ....
-  Lonza Group Ltd.. (10/27/16). "Press Release: Lonza and Clovis Oncology Sign Strategic Long-term Manufacturing Agreement to Secure Supply of Rucaparib". Basel....
-  Lonza Group Ltd.. (10/27/16). "Press Release: Lonza Expects to Reach 2018 Guidance One Year Ahead and Reports Strong Q3 Momentum". Basel....
-  Lonza Group Ltd.. (9/13/16). "Press Release: Lonza Completes Acquisition of InterHealth Nutraceuticals". Basel....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to email@example.com and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)